Cargando…

Role of the latest endovascular technology in the treatment of intermittent claudication

Intermittent claudication is a serious symptom in patients with peripheral arterial disease, and severely limits activities of daily living. Conservative treatment (optimal medical therapy and exercise rehabilitation programs) and revascularization procedures (endovascular treatment [EVT] or open by...

Descripción completa

Detalles Bibliográficos
Autores principales: Ichihashi, Shigeo, Kichikawa, Kimihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074187/
https://www.ncbi.nlm.nih.gov/pubmed/25018633
http://dx.doi.org/10.2147/TCRM.S40161
_version_ 1782323197116416000
author Ichihashi, Shigeo
Kichikawa, Kimihiko
author_facet Ichihashi, Shigeo
Kichikawa, Kimihiko
author_sort Ichihashi, Shigeo
collection PubMed
description Intermittent claudication is a serious symptom in patients with peripheral arterial disease, and severely limits activities of daily living. Conservative treatment (optimal medical therapy and exercise rehabilitation programs) and revascularization procedures (endovascular treatment [EVT] or open bypass surgery) can relieve intermittent claudication. Among these treatment options, EVT has developed dramatically during the past decade, and has enabled physicians to offer less invasive treatment options with increasing durability. EVT for aortoiliac lesions has matured, and its long-term patency now approaches that of open bypass surgery. The latest EVT technologies include drug-eluting stents, stent grafts, drug-coated balloons, and bioresorbable stents. The recently reported patency of stent grafts in the femoropopliteal lesions was comparable with that of the prosthetic bypass graft. In the course of the paradigm shift from bypass surgery to EVT, evidence of any long-term benefit of EVT compared with supervised exercise is still inconclusive. EVT could improve walking performance in the short-term, while supervised exercise could improve walking performance more efficiently in the long-term. Combined treatment with EVT and exercise may offer the most sustainable and effective symptom relief. This paper reviews the relevant literature on the treatment of intermittent claudication, focusing on the latest EVT technologies, and outlines a strategy for achieving long-term benefits.
format Online
Article
Text
id pubmed-4074187
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-40741872014-07-11 Role of the latest endovascular technology in the treatment of intermittent claudication Ichihashi, Shigeo Kichikawa, Kimihiko Ther Clin Risk Manag Review Intermittent claudication is a serious symptom in patients with peripheral arterial disease, and severely limits activities of daily living. Conservative treatment (optimal medical therapy and exercise rehabilitation programs) and revascularization procedures (endovascular treatment [EVT] or open bypass surgery) can relieve intermittent claudication. Among these treatment options, EVT has developed dramatically during the past decade, and has enabled physicians to offer less invasive treatment options with increasing durability. EVT for aortoiliac lesions has matured, and its long-term patency now approaches that of open bypass surgery. The latest EVT technologies include drug-eluting stents, stent grafts, drug-coated balloons, and bioresorbable stents. The recently reported patency of stent grafts in the femoropopliteal lesions was comparable with that of the prosthetic bypass graft. In the course of the paradigm shift from bypass surgery to EVT, evidence of any long-term benefit of EVT compared with supervised exercise is still inconclusive. EVT could improve walking performance in the short-term, while supervised exercise could improve walking performance more efficiently in the long-term. Combined treatment with EVT and exercise may offer the most sustainable and effective symptom relief. This paper reviews the relevant literature on the treatment of intermittent claudication, focusing on the latest EVT technologies, and outlines a strategy for achieving long-term benefits. Dove Medical Press 2014-06-20 /pmc/articles/PMC4074187/ /pubmed/25018633 http://dx.doi.org/10.2147/TCRM.S40161 Text en © 2014 Ichihashi and Kichikawa. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Ichihashi, Shigeo
Kichikawa, Kimihiko
Role of the latest endovascular technology in the treatment of intermittent claudication
title Role of the latest endovascular technology in the treatment of intermittent claudication
title_full Role of the latest endovascular technology in the treatment of intermittent claudication
title_fullStr Role of the latest endovascular technology in the treatment of intermittent claudication
title_full_unstemmed Role of the latest endovascular technology in the treatment of intermittent claudication
title_short Role of the latest endovascular technology in the treatment of intermittent claudication
title_sort role of the latest endovascular technology in the treatment of intermittent claudication
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074187/
https://www.ncbi.nlm.nih.gov/pubmed/25018633
http://dx.doi.org/10.2147/TCRM.S40161
work_keys_str_mv AT ichihashishigeo roleofthelatestendovasculartechnologyinthetreatmentofintermittentclaudication
AT kichikawakimihiko roleofthelatestendovasculartechnologyinthetreatmentofintermittentclaudication